- Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (poster 519)
- Natalizumab reduces the disabling amplitude of multiple sclerosis relapses and improves post-relapse residual disability (poster 524)
These data will be presented in the poster session titled, “Long-Term Treatment Monitoring,” on Friday, 4 October at 3:30 p.m. – 5:00 p.m. CET:
- Disease activity and disability progression decrease beyond 2 years on natalizumab in relapsing MS patients in the TYSABRI ® (natalizumab) Observational Program (poster 1050)
TYSABRI is marketed and distributed by Biogen Idec Inc. For full prescribing information, including boxed warning and important safety information, and more information about TYSABRI, please visit www.biogenidec.com.About Biogen Idec Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. Safe Harbor This press release contains forward-looking statements, including statements about the potential therapeutic effect of TYSABRI in certain patients. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on our current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the occurrence of adverse safety events, failure to comply with government regulation, product liability claims and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.